Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000791823 | SCV000931087 | likely benign | Hypokalemic periodic paralysis, type 1; Malignant hyperthermia, susceptibility to, 5 | 2025-01-18 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001805856 | SCV002050372 | uncertain significance | not provided | 2024-06-12 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Ambry Genetics | RCV002535852 | SCV003529219 | uncertain significance | Inborn genetic diseases | 2021-09-30 | criteria provided, single submitter | clinical testing | The c.4972C>T (p.R1658C) alteration is located in exon 40 (coding exon 40) of the CACNA1S gene. This alteration results from a C to T substitution at nucleotide position 4972, causing the arginine (R) at amino acid position 1658 to be replaced by a cysteine (C). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV003975321 | SCV004790392 | likely benign | CACNA1S-related disorder | 2022-10-04 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |